ZYBERNO
Stock Report
Updated Sep 1, 2026

JAGUAR HEALTH, INC. (JAGX)

Healthcare • NASDAQ

$0.73

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
JAGUAR HEALTH, INC. (JAGX) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-747.5%)
Debt-to-Equity (Solvency Risk):GOOD (0.44x)
Operating Margin (Operational Efficiency):CRITICAL (-246.1%)
Return on Capital (Capital Efficiency):CRITICAL (-872.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

JAGUAR HEALTH, INC. (JAGX) stock report — Zyberno Score 9/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, JAGX generated -$32.29M in Owner Earnings. Capital was deployed as follows: $77.00K invested in capital expenditures. Reinvestment rate: 9.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.73
Market Cap:$2.95M

Valuation Multiples (3)

P/B Ratio:0.60x
P/S Ratio:0.28x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$254.76K
B. Profitability Assessment

Return Metrics (5)

ROA:-92.3%
Reinvestment Rate:9.8%
Fundamental Growth Rate (g):-85.3%

Margin Analysis (3)

Operating Margin Ttm:-246.1%
Net Margin Ttm:-349.6%
Ebitda Margin:-228.1%

TTM Performance (3)

Gross Margin Ttm:59.2%
Operating Margin Ttm:-246.1%
Net Margin Ttm:-349.6%

Yield Metrics (2)

Earnings Yield:-$5.71K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-43.6%
Latest Earnings Filed:2026-08-19

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):8.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.69x
Quick Ratio:0.40x
Cash Ratio:0.15x

Leverage Analysis (3)

Debt To Equity Ttm:0.44x
Debt-to-Equity Ratio:0.44x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-46.00x
Times Interest Earned:-46.00

Capital Structure (4)

Working Capital:-7,847,000.00
Cash And Cash Equivalents:3,788,000.00
Long Term Debt:$873.00K
Net Debt:-$2.70M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $10.52M
Linear Growth: 8.1%
📊 Click to view full JAGX Revenue analysis & methodology →
Cost Of Revenue Ttm:$4.92M

Profitability Breakdown (2)

Gross profit TTM: $6.23M
Linear Growth: -13.0%
📊 Click to view full JAGX Gross Profit analysis & methodology →
-$25.90M

Bottom Line Performance (3)

-$36.78M
Income Before Tax:-$36.92M
Ebitda Ttm:-23,999,000.00

Operating Expenses (5)

Operating Expenses:53,710,000.00
R And D Expense:25,235,000.00
Sga Expense:17,578,000.00
Income Tax Expense:$0.00
Interest Expense:998,000.00

Expense Ratios (3)

R And D To Revenue Percentage:2,060.0%
Sga To Revenue Percentage:1,434.9%
Ebitda Margin:-228.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$34.19M
Current Assets:$17.53M
Ppe Net:417,000.00
Goodwill:0.00
Intangible Assets:$15.09M

Liability Structure (4)

Total Liabilities:29,273,000.00
Current Liabilities:25,380,000.00
Long Term Debt:$873.00K
Short Term Debt:$219.00K

Equity & Capital (3)

Equity:$4.92M
Retained Earnings:-$403.75M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:8,000.00
Inventory:7,316,000.00
Accounts Payable:4,793,000.00

Special Items (2)

Contract Liabilities:468,000.00
Stock Based Compensation:171,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$7.54M-$7.62M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:77,000.00

Financing Activities (3)

Financing Cash Flow:-$6.62M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,896,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-52.27
-$52.27
Earnings Per Share Ttm:-$9.11

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.61
Operating Cash Flow Per Share:-$5.87

Book Value & Capital (2)

Book Value Per Share:$1.22
Cash Per Share:0.94

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.26x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:1,315.25x
Days Sales Outstanding Ttm:0.28

Inventory Management (2)

Inventory Turnover Ttm:0.67x
Days Inventory Outstanding Ttm:542.64

Payables & Cash Cycle (2)

Days Payable Outstanding:355.51
Cash Conversion Cycle:187.41
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$32.29M

Damodaran Growth Analysis (2)

Reinvestment Rate:9.8%
Fundamental Growth Rate (g):-85.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):8.1%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-13.0%
Book Value Growth Rate (Linear):0.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:JAGX
Company Name:JAGUAR HEALTH, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:4.04M
Shares Outstanding Basic:809.12K
Shares Outstanding Diluted:809.12K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 21:15:20 UTC
Data Timestamp:2026-08-22T13:18:45.617629
Scroll to Top